"The agency alleged that Novo Nordisk failed to properly report and/or follow up on three deaths of individuals who were taking semaglutide, the key ingredient in Ozempic and Wegovy. The drugs are part of a broader class of medicine known as GLP-1s that have grown wildly popular for everything from type 2 diabetes to weight loss and are increasingly seen as having potential benefits far beyond those two conditions."
"The popularity of these drugs has led to a sea of GLP-1 offerings flooding the marketnot all of them FDA-approved. GLP-1 drugs, these are the drugs that you've probably heard with those, like, fun advertisement chimes. They're sold as Wegovy and Ozempicthat is the brand name for the active ingredient semaglutide. And then you'll probably have also heard of Zepbound and Mounjaro, which are the brand name for tirzepatide."
GLP-1 drugs, including Ozempic, Wegovy, Zepbound, and Mounjaro, were originally developed as type 2 diabetes treatments but have become increasingly popular for weight loss. These medications work by mimicking glucagonlike peptide 1, a hormone in the body. In March, the FDA issued a warning letter to Novo Nordisk for failing to properly disclose potential risks and report three deaths associated with semaglutide use. The explosive popularity of GLP-1s has led to numerous unapproved alternatives flooding the market. These drugs are now being explored for potential benefits beyond diabetes and weight loss, expanding their therapeutic applications.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]